180 Life Sciences

180 Life Sciences is a NASDAQ-listed biotech (ATNF) with a mission to address high-unmet-need conditions like Dupuytren's disease and frozen shoulder through targeted anti-TNF therapies and novel cannabinoid science. Its strategy is bifurcated, combining a virtual drug development model with an institutional fintech platform, 'Forum,' for securitizing real-world assets. While its lead program is in Phase 2b, the company operates with a lean structure, relying on academic collaborations and CROs, and faces significant challenges in capital allocation and clinical execution amidst a complex dual-focus business model.

A dual-platform approach leveraging deep expertise in localized anti-TNF therapy for fibrosis and the design of novel, non-psychoactive synthetic cannabinoid analogs for inflammation and pain.

In Dupuytren's, competition includes other injectable agents in development (e.g., DexTech Medical) and standard surgical care. The frozen shoulder space lacks dominant pharmacotherapies. The synthetic cannabinoid field is highly crowded with both biotech and pharma players, requiring clear clinical differentiation.